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Abstract
APOBEC3 proteins function to restrict the replication of retroviruses. One mechanism of this restriction is deamination of
cytidines to uridines in (2) strand DNA, resulting in hypermutation of guanosines to adenosines in viral (+) strands.
However, Moloney murine leukemia virus (MoMLV) is partially resistant to restriction by mouse APOBEC3 (mA3) and virtually
completely resistant to mA3-induced hypermutation. In contrast, the sequences of MLV genomes that are in mouse DNA
suggest that they were susceptible to mA3-induced deamination when they infected the mouse germline. We tested the
possibility that sensitivity to mA3 restriction and to deamination resides in the viral gag gene. We generated a chimeric MLV
in which the gag gene was from an endogenous MLV in the mouse germline, while the remainder of the viral genome was
from MoMLV. This chimera was fully infectious but its response to mA3 was indistinguishable from that of MoMLV. Thus, the
Gag protein does not seem to control the sensitivity of MLVs to mA3. We also found that MLVs inactivated by mA3 do not
synthesize viral DNA upon infection; thus mA3 restriction of MLV occurs before or at reverse transcription. In contrast, HIV-1
restricted by mA3 and MLVs restricted by human APOBEC3G do synthesize DNA; these DNAs exhibit APOBEC3-induced
hypermutation.
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Introduction
Mammals have evolved a number of ‘‘restriction’’ factors that
function to block infection by retroviruses and other pathogens.
One of these is the APOBEC3 restriction system. The best-studied
member of the APOBEC3 family is human APOBEC3G (hA3G).
Briefly, hA3G protein is incorporated into HIV-1 particles
produced by infected cells. When these virions infect new target
cells, hA3G deaminates cytidines to uridines in minus-strand DNA
(the initial product of reverse transcription); this results in
replacement of guanosine with adenosine in the coding strand of
proviral DNA. In turn, HIV-1 encodes a protein, ‘‘Vif’’, which
binds to hA3G in the infected cell and brings it to the proteasome
for degradation, thereby interfering with its inclusion in assem-
bling progeny virions [1,2]. The high frequency of G to A (‘‘G:A’’)
mutations is a major, but not the only, mechanism by which hA3G
restricts HIV-1 [3,4,5].
Mice encode only a single APOBEC3 species (‘‘mA3’’). The
overall architecture of mA3 is apparently ‘‘reversed’’ in mA3
relative to hA3G [6,7]. The natural expression of mA3 is known to
function to limit the spread within infected mice of both murine
leukemia viruses (MLVs) [8,9,10,11], which are gammaretro-
viruses, and mouse mammary tumor virus, a betaretrovirus
[12,13,14]. In both of these viruses, mA3 exerts this restriction
without inducing detectable G:A mutations. Thus, it is clear that
mA3 can inhibit retrovirus infection by some mechanism other
than cytidine deamination; this additional mechanism is not yet
understood. On the other hand, some MLV isolates are sensitive
to cytidine deamination by mA3 [15,16,17]; it is striking that the
sequences of endogenous MLV genomes, present within normal
mouse DNA, do contain G:A mutations, indicating that the MLVs
that infected the mouse germline and gave rise to these
endogenous virus genomes were sensitive to mA3-induced
mutation when they infected the germline [18].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38190The effects of mA3 on Moloney MLV (MoMLV), which has
a long history of passage and selection for robust replication in
mice, are somewhat different from its effects on many MLVs
[19,20]. By comparing the restriction of both MoMLV and Vif-
deficient HIV-1 by both mA3 and hA3G, we found that MoMLV
is partially resistant to inactivation by mA3, and that inactivation
of MoMLV by mA3 does not involve G:A mutation. In contrast,
mA3 induces high levels of G:A mutation in Vif-deficient HIV-1.
The mechanism of the partial resistance of MoMLV is completely
unknown, but it does not involve exclusion of mA3 from the
virion, or indeed from the mature core within the virion [19,20].
As Gag is the most abundant protein in the virus particle and
determines the structure of the particle, it seemed possible that
some difference between the Gag proteins of MoMLV and those
of endogenous MLVs might be responsible for the apparent
difference in sensitivity of the viruses to mA3-induced mutation.
We have tested this possibility in the present work. We created
a chimeric MLV in which the gag gene of MoMLV was replaced
by that of a polytropic endogenous MLV. This chimera is fully
infectious, indicating that this ‘‘fossil’’ gag gene is fully functional.
Somewhat surprisingly, the responses of this chimera to both mA3
and hA3G were qualitatively indistinguishable from those of
MoMLV itself: thus Gag does not control sensitivity to restriction
by these APOBEC3s. The data also show that mA3 blocks
infection by MLVs before or at the initiation of reverse
transcription.
Results
Creation of Chimeric MLV
The sequences of the ‘‘polytropic’’ and ‘‘modified polytropic’’
endogenous MLVs show clear evidence of mA3 action during
infectionofthemousegermline[18].WechosePMV19,apolytropic
endogenous MLV in C57BL/6 DNA, as a representative endog-
enous MLV; while this genome contains G:A mutations, the Gag
protein that it encodes has the consensus PMV amino-acid
sequence. As described in Materials and Methods, the PMV19 gag
genewasamplifiedfromC57BL/6DNAandcloned;thegaggenein
an infectious MoMLV molecular clone was then precisely excised,
from the AUG initiator codon to the UAG termination codon, and
replaced with the PMV19 gag gene.
Infectivity of Chimeric MLV
To test the ability of the chimeric MLV genome to produce
infectious MLV particles, we transfected this molecular clone,
together with pBABE-Luc, an MLV-derived retroviral vector
encoding luciferase [20], into 293T cells. Our MoMLV clone was
used as a control in this experiment. Culture fluids were collected
from the transfected cells. The level of MLV particles in the two
samples was quantitated by assaying reverse transcriptase (RT)
activity; the chimera was found to produce approximately the
same amount of virus as MoMLV (data not shown). Cultures of
293 cells expressing the ecotropic MLV receptor, mCAT1, were
then infected with these samples and assayed for luciferase activity.
As shown in Fig. 1, the specific infectivity of the chimeric virus, as
measured by the ratio of luciferase activity to RT activity, was
virtually identical to that of the MoMLV control.
Restriction of Chimeric MLV by mA3 and hA3G
To test the susceptibility of the chimeric MLV to restriction by
mA3 and hA3G, we co-transfected the chimeric MLV clone with
pBABE-Luc and different doses of plasmids encoding the two
APOBEC3s; again, the MoMLV clone was tested in parallel. As
shown in Fig. 2, the chimeric MLV is inactivated by mA3, but
appears to be far more sensitive to hA3G than to mA3; the curves
showing the inactivation of the chimeric virus by both mA3 and
hA3G are very similar to those for MoMLV itself.
We also tested the incorporation of mA3 and hA3G proteins
into chimeric MLV particles by immunoblotting. Samples of
chimeric MLV and MoMLV, prepared by transfection together
with 0, 3, or 10 mg of mA3 or hA3G plasmid, were analyzed; as
both mA3 and hA3G are tagged with a hemagglutinin (HA)
epitope, their levels can be compared in a single immunoblot using
anti-HA antiserum. Profiles of the virion preparations, analyzed
with a broadly reactive anti-CA antiserum, show that there were
similar levels of virus in all of the samples (Fig. 3A). As shown in
Fig. 3B, the two APOBEC3 proteins are packaged at similar levels
in the two viruses; virus made in the presence of 10 mgo f
APOBEC3 plasmid contains more APOBEC3 protein than that
made in 3 mg plasmid. Fig. 3A also shows that the APOBEC3
proteins interfere to some extent with the normal processing of
Pr65
Gag during virus maturation.
Effect of APOBEC3s upon Viral DNA Synthesis
The point in the MLV replication cycle that is blocked by mA3
is not known. We tested the ability of MoMLV and the chimeric
MLV, produced in the presence of mA3 or hA3G, to synthesize
viral DNA upon infecting new cells. The viruses used in these
assays were produced by transfection of 293T cells that had
previously been stably transfected with pLXSH, an MLV-derived
vector encoding the hygromycin phosphotransferase (hph) gene.
Figure 1. Specific infectivity of the viruses. 293T cells were
transiently transfected with an infectious MoMLV or chimera proviral
genome together with the reporter plasmid pBABE-Luc. 293T-mCAT1
cells were then infected with culture supernatants from the transfec-
tants, and lysates of these cells were assayed for luciferase activity.
Virions were assayed for RT activity following precipitation from the
culture supernatants with polyethylene glycol. The graph shows the
luciferase activity divided by the RT activity of the viruses, with the
value for MoMLV set to 100%; thus the data represent the relative
specific infectivities of the samples.
doi:10.1371/journal.pone.0038190.g001
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encoded by the MLV plasmids. The released virions were then
used to infect new 293-mCAT cells and assayed for their ability to
synthesize hph DNA. This protocol helps to eliminate the
background representing DNA from plasmids used to produce
the viruses.
Viruses were produced by transient co-transfections of the
pLXSH-bearing cells with plasmids containing viral genomes; the
MLV-derived luciferase vector pBABE-Luc; and APOBEC3s. The
viral populations produced by the transfected cells will include
some particles with luciferase-vector genomes and some with
pLXSH genomes (as well as some with MLV genomes).
Infectivities were quantitated by the luciferase assay, as in Fig. 2
above, and the infected cells were lysed and assayed for hph DNA
by real-time PCR. Results of these assays are shown in Fig. 4. With
hA3G (Fig. 4A and 4B), the loss of infectivity in both MLVs was
far greater than the reduction in viral DNA synthesis. In contrast,
mA3 inhibited viral DNA synthesis by both viruses to virtually the
same extent as it inhibited infectivity (Fig. 4C and 4D). Somewhat
similar results with MoMLV were presented earlier [20].
We also assayed the cell lysates for minus-strand strong-stop
DNA,theinitialproductofreversetranscription(Fig.4,greenlines).
In all cases, the reduction in strong-stop DNA closely resembled the
reduction in total DNA, as assessed by the hph values.
As a control, we also tested the effect of the APOBEC3s on
DNA synthesis by, as well as infectivity of, DVif HIV-1. As shown
in Fig. 5, the two APOBEC3s were very similar in their effects on
DVif HIV-1: in both cases, the reduction in infectivity far
exceeded the reduction in DNA synthesis.
Sequence Analysis of Viral DNAs Synthesized in Presence
of APOBEC3s
The results in Fig. 4 show that both MoMLV and the chimeric
MLV have not entirely lost the ability to undergo reverse
transcription when they infect fresh cells, despite the presence of
mA3orhA3Ginthevirions.Wealsoperformedsequenceanalysisof
these DNAs to look for G:A mutations, which would be evidence of
cytidine deamination in minus-strand DNA. A stretch of hph DNA
was amplified from the cell lysates and PCR products were
individually cloned and subjected to sequence analysis. As shown
in Table 1, the chimera, like MoMLV [20], does not undergo
a notable increase in the frequency of G:A mutations when it is
inactivated by mA3. In contrast, hA3G increases this frequency
.30-fold.ThehighlevelofG:AmutationsseenintheassaysofDNA
producedbyMLVparticlescontaininghA3G(Table1,5
thto7
thand
11
th and 12
th rows) shows that our experimental techniques are
suitable for detection of these mutations.
Discussion
It has been previously reported that MoMLV, a laboratory
strain of MLV previously subjected to extensive selection for
replication in mice, is partially resistant to restriction by mA3 and
fully resistant to G:A mutation induced by mA3 [19,20]. The
mechanism by which mA3 restricts MoMLV without cytidine
deamination is unknown, as is the mechanism by which MoMLV
evades mA3 restriction: its resistance, unlike the mechanisms by
which other retroviruses resist APOBEC3s, does not involve
exclusion of mA3 from the assembling virion.
The sequences of ‘‘polytropic’’ and ‘‘modified polytropic’’
endogenous MLVs show clear evidence of cytidine deamination
by mA3 at the time that they were inserted into the mouse germline
[18]. It seemed possible that the resistance of MoMLV to mA3 is
attributabletoitsGagprotein,andthatthesensitivityofendogenous
MLVs could be traced to a difference between their Gag proteins
Figure 2. Effects of the different APOBEC3s on the infectivity of
MoMLV and chimera viruses. Virus particles were produced by
transient transfection of viral clones together with pBABE-Luc and 0, 3,
or 10 mg of either mA3 or hA3G expression plasmids. Specific
infectivities were calculated as described in Materials and Methods,
dividing the luciferase activity values by the RT activity values; specific
infectivity of samples produced without APOBEC3 is set to 100%. Black
line, MoMLV with mA3; green, chimera with mA3; red, MoMLV with
hA3G; blue, chimera with hA3G. Results are plotted vs. the quantity of
APOBEC3 plasmid used in the transfections to generate the viruses.
doi:10.1371/journal.pone.0038190.g002
Figure 3. Immunoblotting of virus particles. A) Western blot on
produced virus. Chimera (lanes 1 to 5) or MoMLV (lanes 6 to 10) were
prepared by transient transfection of 293T cells, using 0, 3, or 10 mg
APOBEC3 DNA as well as viral DNA; control cells were transfected with
DNA of pGCcos3Neo (a derivative of pSV2Neo) (lane 11). The culture
supernatants were fractionated as described in Materials and Methods
and equal volumes of culture fluid were loaded into the lanes and
analyzed by immunoblotting against P30
CA. M, molecular weight
markers. B) Encapsidation of different APOBEC3s in MoMLV and
chimera viruses. Virus particles shown in figure 3A were analyzed by
immunoblotting against the HA tag. Equal volumes of culture fluid
were loaded into the lanes.
doi:10.1371/journal.pone.0038190.g003
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MLV, identical to MoMLV except that its gag gene was from
a polytropic endogenous virus, showed the same responses to mA3
(and hA3G) as MoMLV. In future experiments, we will determine
whether sensitivity to mA3 can be mapped to the pol gene of
a sensitive MLV. Many MLVs also produce an alternative, N-
terminallyextendedandglycosylatedformoftheGagprotein,called
‘‘glyco-Gag’’[21,22];wewillalsotestwhether,asrecentlysuggested
[23], this protein is involved in mA3 resistance.
As the mechanism by which mA3 inactivates MLVs is not
known, it was of interest to determine whether these viruses can
undergo reverse transcription when they infect new host cells. We
found that the extent to which MoMLV and the chimeric MLV
lost infectivity under the influence of mA3 was very similar to the
extent to which the viruses lost the ability to synthesize viral DNA
(Fig. 4). Moreover, MLVs inactivated by mA3 are evidently unable
to synthesize even minus strand strong-stop DNA, the initial
product of reverse transcription (Fig. 4, green lines). Thus, mA3
interferes with infection by MLVs either before or at the initial
Figure 4. Comparison of the infectivity of the viruses with the synthesis of the viral DNA. Viruses were prepared by co-transfection of
293T-hygro cells (which contain pLXSH) with viral clones, pBABE-Luc, and 0, 3, or 10 mg of APOBEC3 DNA. 293-mCAT1 cells were then infected with
the resulting culture fluids. Relative specific infectivities (black lines) were determined as in Fig. 2. Parallel cultures were lysed and assayed for hph
DNA (red lines) and strong stop DNA (green lines) as described in Materials and Methods. Values in each assay were divided by the value for the virus
produced with no APOBEC3 plasmid.
doi:10.1371/journal.pone.0038190.g004
Murine Leukemia Viruses and Mouse APOBEC3
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e38190stages of viral DNA synthesis. In contrast, restriction of MLVs by
hA3G and of DVif HIV-1 by mA3 is not at the level of DNA
synthesis, as the degree of viral inactivation in these systems is far
greater than the inhibition of DNA synthesis (Fig. 4A and 4B,
Fig. 5). The viral DNAs synthesized in these cases are, however,
characterized by very high levels of G:A mutation; thus cytidine
deamination is presumably a major contributor to virus in-
activation in these cases. Taken together, these results highlight the
distinctive nature of restriction of MLVs by mA3.
Materials and Methods
Construction of chimeric MLV
To generate a chimeric MLV, we replaced the gag gene in our
infectious clone of MoMLV [20] with the gag gene of the
endogenous MLV PMV19 [18]. Using the specific primer flank-7
(59-GGCAGGAGCCAGGTGTAATGG-39) that anneals in the
PMV19 flanking region and a reverse primer PMV19R1 (59-
GGGGGGCTCCTGACCCTGACCTCCCTAGTCACC-39),
that anneals at the end of PMV19 gag, the PMV19 gag sequence
was isolated from C57BL/6 mouse DNA (Jackson Laboratory, Bar
Harbor, ME).
The chimeric DNA was created using the sequential PCR [24]
approach. The specific PMV19 gag sequence and the MoMLV
proviral genome were used as templates; the amplification primers
contain 59 extensions that are homologous to a portion of the other
target gene. Specifically, the sequences of these primers were 59-
TTT CTG TAT TTG TCT GAG AAT ATG GGA CAG ACC
GTA ACT-39 (PMV19F2); 59- GAA TTC TGA AAG ACC CCA
CCT GTA GG-39 (MoMLV F1); 59-AGT TAC GGT CTG TCC
CAT ATT CTC AGA CAA ATA CAG AAA-39 (MoMLV R1); 59-
CTA ACC TTA GGT GAC TAG GGA GGT CAG GGT CAG -
39(MoMLVF2);and59-GTCGACAAAGAGTTCAAAGGG-39
(MoMLV R2). MoMLV-derived sequences are shown in bold
lettering here. Details of cloning will be provided upon request.
Cells and viruses
Virus particles were produced by transient transfection of 293T
cells, or 293T cells that had previously been stably transfected with
pLXSH plasmid DNA, as previously described [20,25,26].
Plasmids expressing either hA3G or mA3 were a kind gift from
Nathaniel Landau (New York University School of Medicine). The
proteins were both tagged at their C termini with the hemagglu-
tinin (HA) epitope [27]. The mA3 protein encoded by the plasmid
Figure 5. Effect of APOBEC3s on DVif HIV-1 DNA synthesis. 293-
mCAT1 cells were infected with DVif HIV-1. Infectivity and RT activity
were assayed as described [25,29,30]. Twenty-four hours after infection,
the cells were lysed and assayed by real-time PCR for Luciferase DNA
(black and green lines) as described in Materials and Methods [32].
Specific infectivity is represented with red and blue lines.
doi:10.1371/journal.pone.0038190.g005
Table 1. G to A mutation frequencies.
Virus
APOBEC3
Plasmid (mg)
Relative Specific
Infectivity
Nucleotides
Scored G:A Mutations Mutation Frequency
Increase in
Frequency
Moloney None 1 27,086 7 0.00026 1
1 mA3 0.6578 20,018 10 0.0005 1.9
3 mA3 0.4327 19,712 9 0.00046 1.8
10 mA3 0.1571 24,825 30 0.0012 4.6
1 hA3G 0.1381 29,954 217 0.0072 27.9
3 hA3G 0.04814 24,106 299 0.012 47.7
10 hA3G 0.00131 29,698 450 0.015 57.7
Chimera None 1 12,783 9 0.00070 1
3 mA3 0.6762 9,792 7 0.00071 1.02
10 mA3 0.09567 12,160 3 0.00025 0.35
3 hA3G 0.07715 8,832 198 0.022 32.0
10 hA3G 0.00146 11,532 277 0.024 34.3
doi:10.1371/journal.pone.0038190.t001
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previously described [20,25].
Luciferase activity assay
293 cells expressing mouse cationic amino acid transporter 1
(mCAT1, the receptor for ecotropic MLVs; a kind gift of J.
Cunningham, HarvardMedical School) [28]wereinfected with the
filtered culture supernatants. Forty-eight hours after infection, cell
extractswereassayedforluciferaseactivitywiththeLuciferaseAssay
System (Promega, Madison, WI) as previously described [20,25].
Luciferase assays were performed in triplicate; the three values
were, in general, within 10% of each other.
Reverse Transcriptase (RT) Assay
The samples were analyzed for RT activity as previously
described [29,30] following concentration with polyethylene glycol
(PEG) [30]. RT assays were performed in triplicate and the three
values were, in general, within 10% of each other. ‘‘Specific
infectivity’’ is the mean of the luciferase values divided by the
mean of the RT values.
Immunoblotting
Virus particles were isolated from filtered culture fluids by
centrifugation through 20% sucrose (w/w) in phosphate-buffered
saline at 110,0006g for 1 hour at 4uC. The virus pellet was
resuspended in 2xNuPAGE sample buffer (Invitrogen, Carlsbad,
CA).
Immunoblotting against MLV p30
CA was performed with
rabbit polyclonal anti-MLV p30
CA antiserum and against HA-
tagged APOBEC3 proteins with mouse anti-HA monoclonal
antibody 16B12 (Covance, Princeton, New Jersey) as previously
described [20]. Western Lightning Plus-ECL (Perkin Elmer,
Waltham, MA) was used for detection.
Analysis of viral DNA synthesis
The ability of MLV-derived virus particles to perform DNA
synthesis upon infecting new host cells in the presence or absence of
APOBEC3 proteins was assayed as previously described
[20,31,32,33].
Viruses were produced by transient transfection of 293T hygro
cells [26] as mentioned above. The culture supernatants were
treated after filtration with 10 U/ml of DNAse 1 (Ambion, Austin,
TX) and 4 mM MgCl2 for 1 h at 37uC to eliminate contaminating
plasmid DNA from the virus before infecting 293-mCAT1 cells.
An aliquot of the DNAse-treated virus was inactivated by
incubation at 68uC for 20 min and used as control in the
infection. Twenty-four hours after infection, the cells were lysed
and the genomic DNA was extracted by the QIAamp DNA Mini
Kit (Qiagen, Hilden, Germany). The genomic DNA was then
treated with DpnI (New England Biolabs, Ipswich, MA) for 1 h
prior to PCR amplification to further eliminate contaminating
parental plasmid DNA. DNA copy numbers obtained with the
heated virus were indistinguishable from those obtained by
‘‘infecting’’ 293-mCAT1 cells with culture fluid from mock-
transfected 293T hygro cells, and were ,10
24 of the values
obtained in the infected cultures.
AmpliTaq Gold polymerase and associated buffer were
purchased from Applied Biosystems/Life Technologies (Foster
City, CA). A master mix of PCR reagents was prepared such that
the final concentrations in the PCRs for hph DNA were: 1xPCR
buffer; 300 nM dNTPs; 2.5 mM MgCl2; 500nM HPH680F;
500 nM HPH742R; 100 nM 701 probe [31] and 0.06 U/ml
polymerase. Final concentrations of PCR reagents for Luciferase
(luc) DNA were: 1xPCR buffer; 300 nM dNTPs; 2.5 mM MgCl2;
1000 nM LucF; 1000 nM LucR; 260 nM Luc probe [32] and
0.06 U/ml polymerase. Reactions were heated to 95uC for
10 minutes followed by 40 cycles of 95uC for 15 seconds and
60uC for 60 seconds. Final concentrations of PCR reagents for
Strong stop DNA were; 1xPCR buffer; 200 nM dNTPs; 4 mM
MgCl2; 600 nM MLV-SSF4 (59-CGTGTATCCAA-
TAAACCCTCTTGC-39); 600 nM MLV-SSR2 (59-
GCTGACGGGTAGTCAATCACTC-39); 50 nM P-SSMLV-1
probe (59Fam-ATCCGACTTGTGGTCTCGCTGTTCCT-
Tamra 39) and 0.06 U/ml polymerase. Reactions were heated to
95uC for 10 minutes followed by 40 cycles of 95uC for 30 seconds
and 60uC for 30 seconds.
All reactions were performed using a DNA engine Opticon 2
instrument (MJ Instruments, now BioRad, Hercules, CA). DNA
copy numbers were measured in triplicate and the three values
were, in general, within 20% of each other. In the plots of ‘‘DNA
synthesis’’, the mean of the copy numbers is divided by the mean
of the RT values.
G to A hypermutation
DNA was collected from 293-mCAT1 cells that had been
infected with virus carrying the pLXSH vector as described above.
The hph DNA was amplified from 100 ng of the genomic DNA
with hph 2050F (5-AAAGCCTGAACTCACCGCGACGTC-3)
and hph 3030R (5-CACGAGTGCTGGGGCGTCGGTTTC-3)
primers by using Taq polymerase (Invitrogen, Carlsbad, CA) for
35 cycles under the following PCR conditions: 95uC, 45 s; 67.5uC,
1 min; and 72uC, 1 min. The PCR products were cleaned up
using G-50 columns (GE Healthcare, Buckinghamshire, United
Kingdom). The 1-kb PCR product was then ligated into
TOPOTA PCR 2.1-TOPO (Invitrogen, Carlsbad, CA) and
transformed into Top 10 cells following the manufacturer’s
conditions. Colonies were selected by growth on ampicillin-
containing medium. In order to minimize repeated amplification
and cloning of the same DNA, transformed bacteria were only
grown for 30 min before plating. Selected colonies were grown in
1 ml Terrific Broth as described before [20]. The purified DNAs
were sequenced with the M13R primer.
Sequence data were analyzed for mutations by trimming all
sequences to the same length using MEGA version 4 [34] and
aligning them with ClustalW (EMBL-EBI at http://www.ebi.ac.
uk/clustalw/#).
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